Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Cost of Revenue: 2019-2024

Historic Cost of Revenue for Coherus Oncology (CHRS) over the last 6 years, with Dec 2024 value amounting to $117.6 million.

  • Coherus Oncology's Cost of Revenue rose 36.35% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year increase of 34.02%. This contributed to the annual value of $117.6 million for FY2024, which is 26.06% down from last year.
  • Per Coherus Oncology's latest filing, its Cost of Revenue stood at $117.6 million for FY2024, which was down 26.06% from $159.0 million recorded in FY2023.
  • Coherus Oncology's 5-year Cost of Revenue high stood at $159.0 million for FY2023, and its period low was $37.7 million during FY2020.
  • For the 3-year period, Coherus Oncology's Cost of Revenue averaged around $115.5 million, with its median value being $117.6 million (2024).
  • Per our database at Business Quant, Coherus Oncology's Cost of Revenue soared by 126.86% in 2023 and then dropped by 26.06% in 2024.
  • Yearly analysis of 5 years shows Coherus Oncology's Cost of Revenue stood at $37.7 million in 2020, then surged by 52.90% to $57.6 million in 2021, then climbed by 21.69% to $70.1 million in 2022, then spiked by 126.86% to $159.0 million in 2023, then dropped by 26.06% to $117.6 million in 2024.